Company* |
Company* |
Type/Product Area | Terms/Details (Date) |
Abnova Corp.* |
Axela Biosensors Inc.* (Canada) |
Deal to co-develop reagents and biomarker panels for use on Axela's dotLab System |
Abnova will optimize a series of monoclonal antibodies in the effort; terms of the deal were not disclosed (9/27) |
AdnaGen AG* |
Innogenetics NV (Belgium; Euronext:INNX) |
Innogenetics got an option to get rights to technology for isolating fetal red blood cells circulating in maternal blood |
The goal is to develop a diagnostic product for prenatal testing; the monoclonal antibody-based technology is designed to be specific and selective; terms of the deal were not disclosed (9/19) |
Affimed |
XOMA Ltd. (XOMA) |
They entered a cross-license and collaboration agreement covering antibody-related technologies |
XOMA gets rights to technology for antibody discovery, as well as two customized libraries; Affimed gets research rights to XOMA's Bacterial Cell Expression technology; terms were not disclosed (10/2) |
Affymetrix |
NimbleGen Systems Inc.* |
NimbleGen got rights to nucleic acid microarrays and related products and services in the research field |
Terms of the nonexclusive deal were not disclosed; the deal covers manufacturing, use and sales (10/6) |
Algeta ASA* |
Affibody AB* (Sweden) |
Collaboration to develop targeted radiotherapeutics for cancer indications |
Algeta's technology for attaching thorium-227 to peptides and proteins will be used with Affibody's molecules that target tumor cells overexpressing HER2; terms of the deal were not disclosed (8/16) |
Alnylam |
Quark Biotech Inc.* |
Quark got rights to develop and market RNAi therapeutics targeting the p53 and RTP801 genes, for certain diseases |
Alnylam is entitled to up-front and annual payments, as well as potential milestone and royalty payments; also, Quark agreed to not support opposition to Kreutzer- Limmer patents granted in Europe (9/26) |
Alnylam |
Biogen Idec Inc. (BIIB) |
Deal to discover and develop RNAi therapeutics for treating progressive multifocal leukoencephalopathy |
Alnylam gets $5M up front, and could earn more than $51M in milestone payments, as well as royalties on sales; Biogen will fund research (9/20) |
Alnylam |
Calando Pharmaceuticals (majority owned by Arrowhead Research Corp.; ARWR) |
Calando got rights to develop an RNAi drug that uses a synthetic siRNA with its delivery technology, directed at a cancer target |
Calando also has an option to acquire a license for a second target gene; Alnylam is entitled to up-front and annual payments, along with milestone and royalty payments on resulting products (8/17) |
AnorMED |
Poniard Pharmaceuticals Inc. (PARD; formerly NeoRx Corp.) |
They broadened license agreement covering the cancer agent picoplatin |
Poniard gained exclusive worldwide rights under the deal, which also eliminated payment of development milestones and reduced the rate of royalties paid to AnorMED (9/19) |
Aphton Corp. |
Receptor |
Receptor acquired the cancer vaccine Insegia (G17DT), which failed to demonstrate survival benefits in Phase III trials |
The product was acquired in a bankruptcy sale; Receptor believes further development is warranted (7/31) |
A.P. Pharma |
RHEI |
RHEI got rights in greater China to APF530, a product in Phase III for preventing chemotherapy-induced nausea and vomiting |
A.P. gets an up-front fee, and is eligible to receive milestone payments; it would get double-digit royalties on sales (10/2) |
Aradigm Corp. (ARDM) |
Zogenix Inc.* |
Zogenix purchased Aradigm's Intraject subcutaneous delivery technology and related assets |
Aradigm gets $4M up front from newly formed Zogenix, and is eligible to receive a milestone payment and royalties on resulting sales (8/28) |
Arbor Vita |
NoNO Inc.* (Canada) |
Deal to develop and commercialize drugs for treating stroke |
The effort pairs Arbor Vita's PDZ-based discovery platform with NoNO's expertise in neurological disorders; terms were not disclosed (10/16) |
Archemix |
Nuvelo Inc. (NUVO) |
They entered a new deal, replacing previous 50-50 collaboration, to develop short-acting aptamers for cardiovascular indications |
Nuvelo will pay Archemix $4M up front, provide at least $5.25M in research funding over three years and may invest up to $10M upon an Archemix IPO; Archemix also could get $35M in milestone payments per compound, and royalties on sales; it also has a profit-sharing option (8/1) |
Ariad |
Bellicum Pharmaceuticals Inc.* |
Bellicum got nonexclusive rights to use Argent cell- signaling regulation technology in cancer drug development |
Products in this deal will use Ariad's dimerizer drug, AP1903; Ariad gets an equity stake in Bellicum, and is eligible to receive milestone payments (10/11) |
BaroFold Inc.* |
Genentech Inc. (NYSE:DNA) |
Genentech got a research license to PreEMT technology for refolding and producing proteins |
Genentech got an option to obtain a commercial license; terms of the deal were not disclosed (9/7) |
Cardiff |
NuCana Ltd.* (UK) |
NuCana got exclusive rights to a series of ProTide derivatives of licensed and marketed cancer compounds |
Cardiff gets an up-front payment along with potential milestone and royalty payments (9/14) |
Cellartis AB* |
NovaThera (UK) |
Deal to use stem cell technology from Cellartis in development of a platform technology for regenerative medicine |
The effort is part of a UK government- backed program headed by NovaThera focused on production of clinical-grade stem cells; the companies jointly will pursue commercial applications of resulting technology (8/29) |
Cellegy |
ProStrakan Group plc (UK; LSE:PSK) |
ProStrakan is acquiring Cellegesic (nitroglycerin ointment) and three testosterone gel products: Fortigel, Tostrex and Tostrelle |
ProStrakan already was marketing two of the products in Europe; Cellegy will get $9M in cash in the asset sale (9/27) |
CGI |
Genentech Inc. (NYSE:DNA) |
Deal to discover, develop and market compounds against an undisclosed target for use in oncology and autoimmune indications |
CGI gets $25M up front in the form of license fees and an equity investment; it is eligible to receive milestone and option payments exceeding $500M; Genentech's rights are exclusive except in Europe (10/3) |
ChemAxon* |
Evotec AG (Germany; FSE:EVT) |
Evotec licensed technology for use in its informatics platform |
Evotec licensed Chemaxon's entire product line; terms of the deal were not disclosed (9/5) |
Chromos |
Y's Therapeutics Inc.* |
Chromos will engineer a cell line for use in manufacturing a therapeutic protein candidate from Y's |
Chromos will use its ACE System in the effort; terms of the deal were not disclosed (9/21) |
CoGenesys |
Vegenics Ltd.* (Australia) |
Vegenics got worldwide rights to technology in the field of vascular endothelial growth factors |
CoGenesys gets an up-front licensing fee, and is entitled to development milestone payments and royalties on any resulting sales (8/21) |
CogState Ltd. |
Pacific Northwest Biotechnology Inc.* |
Pacific Northwest licensed the preclinical drug candidate AT4, which is directed at the angiotensin 4 receptor |
CogState is entitled to milestone payments in the deal, and would get a royalty rate of 1% on any resulting sales (8/21) |
Crucell NV |
ADImmune Corp.* (Taiwan) |
ADImmune got rights to use PER.C6 cell line technology to develop a vaccine against Japanese encephalitis virus |
Crucell is entitled to a license fee, annual maintenance fees and royalties on any sales; ADImmune would sell resulting products in Taiwan and China (10/11) |
Crucell NV |
MorphoSys AG (Germany; FSE:MOR) |
MorphoSys got rights to use the PER.C6 cell line to produce clinical-grade material for its MOR103 antibody program |
It was MorphoSys' second license to the technology; terms of the deal were not disclosed (8/17) |
Debiopharm |
Salix Pharmaceuticals Ltd. (SLXP) |
Salix got exclusive U.S. rights to Sanvar IR, which is in Phase III trials for treating acute esophageal variceal bleeding |
Debiopharm is entitled to up to $14M in up- front and regulatory and sales milestone payments, as well as royalties on resulting sales (9/5) |
Depomed |
Patheon Inc. (Canada; TSX:PTI) |
Patheon gained access to Depomed's AcuForm drug delivery technology |
Patheon can use the technology in work on pharmaceutical products with its partners; license agreements would be formed for resulting products (8/7) |
Diamyd Medical |
Neurologix Inc. (OTC BB: NRGX) |
Neurologix got a license to to use the glutamic acid decarboxylase 65 gene, a component of its NLX-P101 gene therapy |
Diamyd gets a $0.5M license fee, and annual maintenance fees; it also could get certain milestone and royalty payments on the Parkinson's disease product (8/7) |
DNAPrint |
NeoCodex Inc.* (Spain) |
DNAP will provide DNA sampling for research on the effectiveness of treatments for ovarian cancer |
DNAP will work to identify genes of further interest, based on the drug response data provided by NeoCodex; terms of the deal were not disclosed (8/22) |
Dyax Corp. |
Trubion Pharmaceuticals Inc. (TRBN) |
Dyax will use its phage display libraries to discover compounds that bind to Trubion oncology and inflammation targets |
Dyax is entitled to up-front and FTE payments under the nonexclusive deal, as well as potential milestone and royalty payments (9/5) |
Dyax Corp. (DYAX) |
Serono SA (Switzerland; NYSE:SRA) |
Serono got nonexclusive rights to use antibody phage display libraries in antibody discovery and development |
Dyax also will perform funded research on certain targets; Dyax gets maintenance and research payments, and is eligible to receive milestone and royalty payments (9/7) |
ESBATech AG* |
Oncalis AG*(Switzerland) |
ESBATech spun out its small- molecule inhibitor programs to form Oncalis |
Oncalis is being financed by ESBATech's Series A investors; terms of the deal were not disclosed (9/6) |
Exiqon A/S* |
Luminex Corp. (LMNX) |
Deal to to co-develop and commercialize microRNA products |
Products will be based on Luminex's xMAP technology and Exiqon's Locked Nucleic Acid technology; terms were not disclosed (9/19) |
GammaCan |
Life Therapeutics Inc.(ASX:LFE) |
Deal to develop GammaCan's VitiGam, an intravenous IgG- based immunotherapy for cancer indications |
They will share development costs and would share any resulting proceeds in the same proportion (8/22) |
Genizon |
Genentech Inc. (NYSE:DNA) |
Genentech got an exclusive license to Genizon's GeneMap of disease- associated genes in Crohn's disease |
The data come from a study of the Quebec Founder Population; Genizon gets an up- front payment and research funding, and could get milestone payments on resulting products (8/8) |
GenPat77 |
Medarex Inc. (MEDX) |
Deal to develop fully human antibody products against disease targets provided by GenPat77 |
Medarex technology will be used to generate the antibodies; they will share development and commercialization responsibilities on resulting products; other terms were not disclosed (8/22) |
GPC Biotech |
Kinaxo Biotechnologies GmbH* (Germany) |
Kinaxo got rights to use GPC's KinaTor technology in fee-for-service activities |
The technology is used to identify protein targets; Kinaxo gets exclusive, worldwide rights in that area and the right to sublicense the technology (7/27) |
Immunicon |
MolMed SpA* (Israel) |
Deals under which Immunicon will develop a biomarker for tumor endothelial cells, and analyze cell data from a Phase I trial |
The work focuses on MolMed's vascular- targeting compound Aregyr for cancer; terms of the deal were not disclosed (9/28) |
Infinity |
MedImmune Inc.(MEDI) |
Deal to develop and market small-molecule cancer drugs targeting heat-shock protein 90 and the Hedgehog pathway, programs from Infinity |
Infinity gets $70M up front, and up to $430M in late-stage milestone payments; they will share costs and any resulting profits; Infinity retained a U.S. co-promotion option (8/28) |
InNexus |
EvoGenix Ltd. |
Deal to use InNexus technology with an antiviral antibody being developed by EvoGenix |
InNexus will apply its SuperAntibody technology to the antibody; terms of the deal were not disclosed (10/3) |
InNexus |
BioInvent International AB (Sweden; SSE:BINV) |
Deal to use InNexus technology with a BioInvent therapeutic antibody- targeting cancer |
The work will be aimed at a single target; financial terms, and details on future development, were not disclosed (9/27) |
InPharma |
Cytogen Corp. (CYTO) |
Cytogen got exclusive North American rights to the oral mucositis product Caphosol |
InPharma gets $5M up front and $1M more after six months; it also is entitled to royalties and sales-based milestones; Cytogen also got an option to acquire rights in Europe and Asia (10/11) |
Juvantia |
Santhera Pharmaceuticals AG* (Switzerland) |
Deal to develop Juvantia's fipamezole, which was in Phase IIa testing for treating dyskenesia in Parkinson's disease patients |
Santhera will conduct further development, and has an option to acquire the product through the purchase of Juvantia; terms of the deal were not disclosed (9/5) |
Karo Bio |
Radius* |
Radius got worldwide rights, excluding Nordic countries, to a new class of selective androgen-receptor modulators |
Milestone payments to Karo for one product could total $17M; it also could get payments for other products and royalties on resulting sales (9/12) |
LBS |
Enzo Biochem Inc. (NYSE:ENZ) |
Enzo got rights to patents related to non-PCR-based RNA amplification |
The technology provides increased amplification from relatively small RNA samples in gene expression studies; terms of the deal were not disclosed (10/13) |
Medinox Inc.* |
Logical Therapeutics Inc.* |
Logical got exclusive rights to develop the NSAID agent LT-NS001 in North America, Europe and Australia |
Medinox gets an up-front payment, and is eligible to receive development and regulatory milestones, as well as royalties on resulting sales (9/5) |
Medivir AB |
Epiphany Biosciences* |
Epiphany got rights to MIV-606, Medivir's Phase II compound against varicella zoster virus and other viruses |
Medivir gets equity in Epiphany, and is eligible to receive up to $24.5M in milestone payments, as well as royalties on sales; Medivir retained rights in the Nordic countries (9/8) |
MGI Pharma |
Medicure Inc. (Canada; TSX:MPH) |
Medicure acquired exclusive U.S. rights to Aggrastat, a GP IIb/IIIa inhibitor approved for treating acute coronary syndrome |
MGI had acquired the U.S. rights through its acquisition of Guilford Pharmaceuticals Inc., which got the rights from Merck & Co. Inc.; MGI gets $19M in the deal, and Merck gets royalty payments (8/9) |
MolecularMD* |
Breakthrough Therapeutics* |
MolecularMD will monitor disease levels in patients participating in a Phase II trial from Breakthrough |
The trial is testing Breakthrough's Ablvax (VAX100) vaccine in patients with resistant chronic myeloid leukemia; terms were not disclosed (8/30) |
MondoBiotech |
Biogen Idec Inc. (BIIB) |
Biogen got rights to develop and market Aviptadil, a Phase II compound for treating pulmonary arterial hypertension |
Mondo gets $7.5M up front, and up to $30M in milestone payments, as well as royalties on any resulting sales; also, Biogen would invest $5M in Mondo's initial public offering (9/14) |
Multispan |
Medarex Inc. (MEDX) |
Medarex got rights to HEx GPCR overexpressing cell lines for use as whole-cell immunogens |
Specific targets and financial details were not disclosed (10/12) |
Newron |
Serono SA (Switzerland; NYSE:SRA) |
Serono got exclusive rights to the Phase III product safinamide in Parkinson's disease, Alzheimer's disease and other cognitive disorders |
Newron is eligible to receive up to $200M in up-front and milestone payments, as well as royalties on resulting sales; Newron also got co-promotion options in Italy and Spain (10/16) |
Oncalis AG* |
ChemDiv Inc.* |
Deal to discover and develop compounds that inhibit receptor tyrosine kinase and other cancer- related targets |
Each will contribute technologies to the effort; terms of the deal were not disclosed (10/3) |
Oncovir Inc.* |
Nventa Bio- pharmaceuticals Corp. (TSX:NVN) |
Nventa gets rights to use the adjuvant Hiltonol, or Poly-ICLC, which targets the Toll-like receptor 3 pathway |
Nventa will use Hiltonol with its HspE7 vaccine for treating human papillomavirus-related diseases; terms of the deal were not disclosed (8/23) |
Oxford Gene |
Bio Matrix Research Inc.* (Japan) |
Bio Matrix got rights to OGT patents on oligonucleotide microarrays |
Bio Matrix got rights to develop, manufacture and market microarrays in Japan; terms of the deal were not disclosed (8/15) |
Oxford Gene |
Filgen Inc.* (Japan) |
Filgen got rights to OGT patents on oligonucleotide microarrays |
Filgen got rights to conduct a microarray service in Japan; terms of the deal were not disclosed (8/15) |
PharmaNova |
Depomed Inc. (DEPO) |
Depomed got rights to patents covering the use of gabapentin for the treatment of menopausal hot flashes |
The goal under the exclusive sublicense to patents held by the University of Rochester is to develop a non- hormonal treatment for hot flashes; PharmaNova gets $0.5M up front, and is eligible to receive milestone and royalty payments in that indication (10/18) |
Phynova |
Botanic Century Co. Ltd.* (China) |
They signed a a letter of intent under which Phynova would acquire a 45% stake in Botanic Century, and get an option to increase it to 51% |
Phynova would pay about $1M in cash and shares, mostly cash, for the stake; also, Botanic licensed Phynova's PYN18 hepatitis C product for the Chinese market (8/7) |
Predix |
Amgen Inc. (AMGN) |
Collaboration to develop oral S1P1 modulators for treating autoimmune diseases; the focus is both existing preclinical compounds from Predix and new compounds |
Predix gets $20M up front and up to $287.5M more in milestone payments; it also could get double-digit royalties on resulting sales (7/31) |
PrimeCell |
Regeneration Technologies Inc. (RTIX) |
Deal to pursue orthopedic applications using PrimeCell's germ cell reprogramming technology |
They will evaluate the use of stem cells in conjunction with biological implants for improving orthopedic grafts; terms of the deal were not disclosed (8/23) |
ProMetic Life |
Nabi Bio- pharmaceuticals (NABI) |
Nabi got rights to use ProMetic's plasma fractionation technology in the manufacture of its Civacir and Altastaph products |
Nabi got exclusive rights to use the technology with those products, and an option (Canada; TSX:PLI) for exclusive North American rights to use it with Nabi-HB (8/29) |
ProMetic Life |
Nabi Bio- pharmaceuticals (NABI) |
Nabi got rights to use ProMetic's Mimetic Ligands technology in the manufacturing of certain plasma-derived hyperimmune products |
ProMetic is entitled to milestone payments of up to $18M based on BLA filings and approvals, and would get royalties on resulting sales (8/21) |
QLT Inc. |
BioDelivery Sciences International Inc. (BDSI) |
BDSI purchased all rights outside the U.S. to BEMA drug delivery technology, for $3M |
Prior to the deal, BDSI had licensed BEMA from QLT USA Inc. on a worldwide, exclusive basis; BDSI has an 12-month option to acquire U.S. rights for another $7M (8/3) |
Ryogen LLC* |
OriGene Technologies Inc.* |
OriGene got nonexclusive rights to patents covering the Aminopeptidase P gene |
The gene is a marker for a number of dis- eases; terms of the deal were not disclosed (8/15) |
Santaris |
Enzon Pharmaceuticals Inc. (ENZN) |
Enzon licensed two preclinical candidates, SPC2968 and SPC3042, and six other compounds that will be directed against cancer targets |
The RNA antagonists are based on Santaris' locked nucleic acid technology; Enzon gets rights outside Europe; Santaris gets $8M up front, up to $200M in milestone payments and royalties on any resulting sales (7/27) |
StemCells |
Stem Cell Therapeutics Corp. (Canada; CDNX:SSS) |
Stem Cell Therapeutics got a license to use technology in the neural stem cell field |
StemCells is entitled to up-front and maintenance fees, as well as milestone and royalty payments; it also got rights to use SCT technology in R&D, and would receive royalties on resulting products (8/29) |
Synphora |
Biovitrum AB (Sweden; SSE:BVT) |
Biovitrum gained an option to acquire Synphora's Phase I psoriasis candidate JB991, a prostaglandin derivative |
Biovitrum will contribute up to SEK5M ($0.68M) to help fund trials through Phase II; it would have an option to acquire the product after Phase IIa trials (10/10) |
Syntonix |
Serono SA (Switzerland; NYSE:SRA) |
Serono got an option to develop Syntonix's FSH:Fc SynFusion products, focused on a long-acting, inhaled treatment for infertility |
Syntonix gets up-front and option fees; if the option is exercised, Syntonix would get additional up-front fees and be eligible for up to $54M in milestone payments, as well as royalties on resulting sales (9/18) |
Theragenex |
Zylera Pharmaceuticals* |
Zylera got rights to use Theragenix technologies in development of several products |
Terms were not disclosed, but the deal provides for sharing any resulting revenues (8/30) |
Tissue |
Bioheart Inc.* |
Bioheart got an option to acquire worldwide rights to adipose-derived therapeutic cell technology |
Bioheart could gain exclusive rights to use the technology for heart attacks and heart failure; Tissue Genesis would be entitled to up-front and milestone payments (8/8) |
Tripos Inc. |
CeNeS Pharmaceuticals plc (UK; AIM:CEN) |
They extended deal to develop catechol-O-methyltransferase inhibitors to treat Parkinson's disease |
They began the collaboration in 2003; terms of the deal were not disclosed (9/12) |
Vaccinex Inc.* |
OPi SA* (France) |
OPi got worldwide rights to OPR-003, a fully human anti-interleukin-6 antibody |
Vaccinex is eligible to receive milestone and royalty payments in the deal; it also has certain co- development options (10/10) |
Valentis Inc. |
Inovio Biomedical Corp (AMEX:INO) |
Inovio acquired certain DNA delivery and expression assets, including the DNAvax polymer delivery system and GeneSwitch gene regulation technology |
It also acquired rights under existing Valentis license agreements; Inovio paid $0.8M, of which $0.3M was offset by an existing debt; Valentis two weeks earlier entered a merger agreement with Urigen NA Inc. (10/17) |
XOMA Ltd. |
Attenuon LLC* |
XOMA will humanize a monoclonal antibody targeting the urokinase plasminogen activator system |
The antibody is being developed for cancer indications; XOMA gets an up-front fee, and could get milestone and royalty payments (10/3) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
# Item occurred before the time frame of this chart but was not included in the previous chart. | |||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; PK = Pink Sheets; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange. | |||
